×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALPMY – astellas pharma unsp/adr (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALPMY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/22
07:17 am
alpmy
Astellas Pharma (TSE:4503): Exploring Valuation After Strong 21% Monthly Share Price Rally [Yahoo! Finance]
Low
Report
Astellas Pharma (TSE:4503): Exploring Valuation After Strong 21% Monthly Share Price Rally [Yahoo! Finance]
11/19
09:52 am
alpmy
Lung Transplant Rejection Research Report 2025-2035: TFF Pharmaceuticals and Astellas Lead by Investing Heavily in R&D to Improve Existing Immunosuppressive Therapies, and Develop New Biologics [Yahoo! Finance]
Low
Report
Lung Transplant Rejection Research Report 2025-2035: TFF Pharmaceuticals and Astellas Lead by Investing Heavily in R&D to Improve Existing Immunosuppressive Therapies, and Develop New Biologics [Yahoo! Finance]
10/24
05:32 am
alpmy
Astellas Pharma (OTCMKTS:ALPMY) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Astellas Pharma (OTCMKTS:ALPMY) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
10/23
08:00 am
alpmy
Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA)
Low
Report
Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA)
10/22
08:00 am
alpmy
Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
Low
Report
Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
10/21
07:30 pm
alpmy
PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
Low
Report
PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
10/19
07:53 pm
alpmy
IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety [Yahoo! Finance]
Low
Report
IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety [Yahoo! Finance]
10/19
07:30 pm
alpmy
IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
Low
Report
IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/9
Astellas Announces Acceptance of XOSPATA® (gilteritinib) for Regulatory Review in China by the National Medical Products Administration
3.4%
12/17 FDA OKs expanded use of Astellas and Pfizer's Xtandi [Seeking Alpha] 2.5%
8/6 Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms 2.4%
10/30 Pandion and Astellas Announce Collaboration to Deliver Pancreas-Targeted Immunomodulators 1.8%
12/5 Astellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative Science 1.5%
1/23 ASTELLAS PHARMA/ADR (OTCMKTS: ALPMY) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock. 1.3%
9/20 Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation 1.0%
7/10 Astellas Appoints Chelsea Glinski as National Vice President Oncology Sales 0.6%
1/15 Astellas Completes Acquisition of Audentes Therapeutics 0.3%
1/31 UPDATE 2-Astellas Pharma keeps profit forecast as prostate cancer drug sales rise [Reuters] 0.2%
12/17 FDA OKs expanded use of Astellas and Pfizer's Xtandi [Seeking Alpha] 2.5%
8/6 Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms 2.4%
10/30 Pandion and Astellas Announce Collaboration to Deliver Pancreas-Targeted Immunomodulators 1.8%
12/5 Astellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative Science 1.5%
1/23 ASTELLAS PHARMA/ADR (OTCMKTS: ALPMY) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock. 1.3%
9/20 Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation 1.0%
7/10 Astellas Appoints Chelsea Glinski as National Vice President Oncology Sales 0.6%
1/15 Astellas Completes Acquisition of Audentes Therapeutics 0.3%
1/31 UPDATE 2-Astellas Pharma keeps profit forecast as prostate cancer drug sales rise [Reuters] 0.2%
TOP News Decliners
5/30
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib)
-3.8%
2/11 ASTELLAS PHARMA/ADR (OTCMKTS: ALPMY) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock. -3.6%
10/1 ASTELLAS PHARMA/ADR (OTCMKTS: ALPMY) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -1.7%
7/31 Q1/2019 6/30/2019 EPS 35.580 ZacksConsensus N/A ActVsEst N/A - N/A -1.4%
11/20 Astellas and Welldoc Enter into Strategic Alliance for Digital Therapeutics -1.3%
10/1 Astellas Commits Nearly $13 Million to Fund Boston-Area Start-Up Innovation in Cell and Gene Therapy -1.3%
9/11 Astellas Partners with MBC BioLabs to Help Pioneering Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts -1.3%
3/26 ASTELLAS PHARMA/ADR (OTCMKTS: ALPMY) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. -1.1%
5/20 Astellas Oncology Announces C³ Prize® Call for Entries to Award $200,000 to the Best Ideas in Cancer Care Beyond Medicine -0.9%
7/31 Q1/2019 6/30/2019 EPS 35.580 ZacksConsensus N/A ActVsEst N/A - N/A -0.8%
2/11 ASTELLAS PHARMA/ADR (OTCMKTS: ALPMY) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock. -3.6%
10/1 ASTELLAS PHARMA/ADR (OTCMKTS: ALPMY) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -1.7%
7/31 Q1/2019 6/30/2019 EPS 35.580 ZacksConsensus N/A ActVsEst N/A - N/A -1.4%
11/20 Astellas and Welldoc Enter into Strategic Alliance for Digital Therapeutics -1.3%
10/1 Astellas Commits Nearly $13 Million to Fund Boston-Area Start-Up Innovation in Cell and Gene Therapy -1.3%
9/11 Astellas Partners with MBC BioLabs to Help Pioneering Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts -1.3%
3/26 ASTELLAS PHARMA/ADR (OTCMKTS: ALPMY) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. -1.1%
5/20 Astellas Oncology Announces C³ Prize® Call for Entries to Award $200,000 to the Best Ideas in Cancer Care Beyond Medicine -0.9%
7/31 Q1/2019 6/30/2019 EPS 35.580 ZacksConsensus N/A ActVsEst N/A - N/A -0.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: